Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials

Reuters

昨天

Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has announced its intention to initiate a Q-Submission to the U.S. Food and Drug Administration (FDA) related to its Gen-2 SYNC system. This regulatory process aims to facilitate dialogue with the FDA regarding the clinical trial design for treating Alzheimer's disease, dementia, and mild cognitive impairment $(MCI)$. The company's decision follows encouraging internal data and preliminary feedback from the FDA. Nexalin's Gen-2 SYNC system, featuring technical enhancements and a proprietary 15 milliamp advanced waveform, is positioned as a promising non-invasive therapeutic option for cognitive conditions. The company views this regulatory milestone as a critical step towards advancing its neuromodulation platform for cognitive and neuropsychiatric disorders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442812-en) on May 01, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2532001319"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532001319\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532001319?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-01 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532001319","market":"us","top_or_hot":-1,"title":"Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NXL\">Nexalin Technology, Inc.</a> (Nasdaq: NXL; NXLIW) has announced its intention to initiate a Q-Submission to the U.S. Food and Drug Administration (FDA) related to its Gen-2 SYNC system. This regulatory process aims to facilitate dialogue with the FDA regarding the clinical trial design for treating Alzheimer's disease, dementia, and mild cognitive impairment <a href=\"https://laohu8.com/S/MCI\">$(MCI)$</a>. The company's decision follows encouraging internal data and preliminary feedback from the FDA. Nexalin's Gen-2 SYNC system, featuring technical enhancements and a proprietary 15 milliamp advanced waveform, is positioned as a promising non-invasive therapeutic option for cognitive conditions. The company views this regulatory milestone as a critical step towards advancing its neuromodulation platform for cognitive and neuropsychiatric disorders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442812-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-01 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NXL\">Nexalin Technology, Inc.</a> (Nasdaq: NXL; NXLIW) has announced its intention to initiate a Q-Submission to the U.S. Food and Drug Administration (FDA) related to its Gen-2 SYNC system. This regulatory process aims to facilitate dialogue with the FDA regarding the clinical trial design for treating Alzheimer's disease, dementia, and mild cognitive impairment <a href=\"https://laohu8.com/S/MCI\">$(MCI)$</a>. The company's decision follows encouraging internal data and preliminary feedback from the FDA. Nexalin's Gen-2 SYNC system, featuring technical enhancements and a proprietary 15 milliamp advanced waveform, is positioned as a promising non-invasive therapeutic option for cognitive conditions. The company views this regulatory milestone as a critical step towards advancing its neuromodulation platform for cognitive and neuropsychiatric disorders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442812-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL1XlRyH:1","article_id":"2532001319","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532001319","pubTimestamp":1746109814,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nexalin Technology, Inc.  has announced its intention to initiate a Q-Submission to the U.S. Food and Drug Administration  related to its Gen-2 SYNC system. This regulatory process aims to facilitate dialogue with the FDA regarding the clinical trial design for treating Alzheimer's disease, dementia, and mild cognitive impairment . The company's decision follows encouraging internal data and preliminary feedback from the FDA. Nexalin's Gen-2 SYNC system, featuring technical enhancements and a proprietary 15 milliamp advanced waveform, is positioned as a promising non-invasive therapeutic option for cognitive conditions. The company views this regulatory milestone as a critical step towards advancing its neuromodulation platform for cognitive and neuropsychiatric disorders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Nexalin Technology Inc.通过FDA Q提交阿尔茨海默氏症和痴呆症临床试验推进Gen-2 SYNC系统","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NXL":0.9},"content_text":"Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials\n    \n\nNexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has announced its intention to initiate a Q-Submission to the U.S. Food and Drug Administration (FDA) related to its Gen-2 SYNC system. This regulatory process aims to facilitate dialogue with the FDA regarding the clinical trial design for treating Alzheimer's disease, dementia, and mild cognitive impairment $(MCI)$. The company's decision follows encouraging internal data and preliminary feedback from the FDA. Nexalin's Gen-2 SYNC system, featuring technical enhancements and a proprietary 15 milliamp advanced waveform, is positioned as a promising non-invasive therapeutic option for cognitive conditions. The company views this regulatory milestone as a critical step towards advancing its neuromodulation platform for cognitive and neuropsychiatric disorders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442812-en) on May 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}